News

Townsquare Media Preps for Q3 2024 Earnings Call Announcement

Townsquare Media Preps for Q3 2024 Earnings Call Announcement

Townsquare Media Plans Conference Call for Q3 2024 Results

Townsquare Media, Inc. (NYSE: TSQ), a prominent player in the digital media and marketing industry, has announced its strategy for discussing its financial performance as the third quarter of 2024 draws to a close. The company is set to release its financial results on the morning of November 7, 2024, prior to the stock market opening. This marks an important moment for stakeholders, marking a quarter laden with opportunities and challenges.

Details of the Conference Call

The conference call geared toward discussing the third quarter results will take place on November 7, 2024, at 10:00 a.m. Eastern Time. In the ever-evolving landscape of media and advertising, this call serves as a vital touchpoint for investors and analysts alike to gain insights into the company’s operational health and marketing strategies.

To join the discussion, participants can dial 1-800-717-1738 from the U.S. or Canada, or 1-646-307-1865 for those calling internationally. Attendees will need the conference ID, which is “Townsquare,” to enter the call seamlessly.

Accessing the Replay

For those unable to attend, a telephone replay of the call will be accessible until November 14, 2024. Interested parties can access the replay by calling 1-844-512-2921 within the U.S. or Canada, or 1-412-317-6671 from other locations, inputting confirmation code 1142541. Furthermore, a web-based archive of the call will be made available for later listening on the corporate investor relations website.

About Townsquare Media, Inc.

Townsquare Media stands out as a leading community-focused company in the digital media and marketing space. With a significant focus outside the largest 50 markets in the U.S., the company finds its strength in local radio platforms alongside a robust mix of digital services. Notably, their subscription-based service, Townsquare Interactive, caters to around 23,575 small to medium-sized businesses (SMBs), offering services ranging from website creation and hosting to search engine optimization and social media management.

Diverse Digital Advertising Portfolio

In addition to its marketing solutions, Townsquare boasts an extensive digital advertising platform under the name Townsquare Ignite. This innovative division combines localized news sites and mobile applications with major national music brands, aggregating valuable first-party data. They leverage proprietary digital programmatic advertising technology to deliver high-performing ad solutions that resonate with local audiences.

Commitment to Local Media

With a portfolio consisting of 349 local terrestrial radio stations in 74 markets, strategically situated outside the major cities, Townsquare remains committed to amplifying local content. Brands like WYRK.com and NJ101.5.com enrich their offering with a plethora of entertainment and information, enhancing community connectivity.

Frequently Asked Questions

What is the purpose of the Townsquare conference call?

The call aims to discuss Townsquare Media's financial results for the third quarter of 2024 and provide insights into its business performance and strategies.

How can I participate in the conference call?

To join the conference call, dial 1-800-717-1738 or 1-646-307-1865, using the conference ID “Townsquare” on November 7, 2024, at 10:00 a.m. Eastern Time.

Will there be a replay of the conference call?

Yes, a replay of the call will be available until November 14, 2024, through specific dial-in numbers provided by the company.

What services does Townsquare Interactive offer?

Townsquare Interactive provides a variety of digital marketing services including website design, SEO, and social media management, primarily serving SMBs.

What is the significance of Townsquare's local media portfolio?

The local media portfolio allows Townsquare to connect deeply with communities outside major markets, delivering localized content and advertising solutions tailored to specific audience needs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 24

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 99

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading